Until is a medical technology company focused on organ-scale reversible cryopreservation. Its work aims to extend the viability of donated organs for transplant by preserving them at subzero temperatures without the formation of ice crystals - a process known as vitrification - and rewarming them uniformly when needed.
The company's core product is an engineered system for safely and reversibly cryopreserving human organs. The workflow operates across five integrated dimensions: perfusion, cryoprotectant management, controlled cooling, uniform rewarming, and post-preservation assessment of organ health. The approach draws on expertise in cryobiology, cryoprotectant chemistry, and specialised thermal engineering.
Until's technology addresses a persistent bottleneck in transplant medicine: the narrow time window between organ procurement and transplantation. Current cold-storage methods limit most organs to hours of viability, constraining transplant logistics and contributing to organ shortages. By enabling long-term preservation without cellular damage, the company's systems could broaden geographic matching between donors and recipients and reduce the number of viable organs that go unused.
